Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620603 · ClinicalTrials.gov registry record · Phase 1
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
A Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis, sponsored by Case Comprehensive Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04620603 is a Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis that is active but no longer recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 5 participants, below the 126-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04620603, a Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis, is active but no longer recruiting, sponsored by Case Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.
Conditions Studied
Interventions
- RADIATION Low Dose Rate Brachytherapy (LDR)
- DRUG Standard-of-Care Immunotherapy
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620603
The ClinicalTrials.gov registry entry for NCT04620603 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Renal Cell Cancer appearing as the primary indexed condition, and to 2 interventions - of which Low Dose Rate Brachytherapy (LDR) is the first listed.
NCT04620603 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04620603 about?
NCT04620603 is a clinical study titled "Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer". This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.
What is the current status of trial NCT04620603?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-05-27. Estimated completion is 2026-02-01.
What conditions does trial NCT04620603 study?
This clinical trial studies the following conditions: Renal Cell Cancer, Urothelial Cancer of Renal Pelvis, Cutaneous Malignant Melanoma.
What interventions are being tested in trial NCT04620603?
The interventions under investigation include: Low Dose Rate Brachytherapy (LDR) (RADIATION), Standard-of-Care Immunotherapy (DRUG).
Who is sponsoring clinical trial NCT04620603?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04620603 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
RECRUITING · Phase 1
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
COMPLETED
-
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.